PHILADELPHIA, PA — August 27, 2025 — Leads & Copy — Context Therapeutics Inc. (Nasdaq: CNTX) will participate in the Cantor Global Healthcare Conference 2025, with a fireside chat on Wednesday, September 3 at 10:55 AM ET in New York, NY, and 1×1 meetings on September 3. The company will also participate in the H.C. Wainwright 27th Annual Global Investment Conference, with a fireside chat on Monday, September 8 at 3:30 PM ET in New York, NY, and 1×1 meetings on September 8.
For additional information or to request a meeting with Context’s management team during these events, please contact your conference representative or IR@contexttherapeutics.com.
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia.
Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com
Source: Context Therapeutics Inc.
